2021
A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage
Martini RP, Siler D, Cetas J, Alkayed NJ, Allen E, Treggiari MM. A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage. Neurocritical Care 2021, 36: 905-915. PMID: 34873674, DOI: 10.1007/s12028-021-01398-8.Peer-Reviewed Original ResearchConceptsSoluble epoxide hydrolaseAneurysmal subarachnoid hemorrhageSubarachnoid hemorrhageDHET ratiosEnd pointDay 7Day 10Primary study end pointSoluble epoxide hydrolase inhibitionCSF inflammatory cytokinesEET/DHET ratiosIncidence of DCIPrevention of DCITertiary end pointSecondary end pointsStudy end pointCerebral blood flowLength of stayEndothelial injury biomarkersEpoxide hydrolase inhibitionNeurovascular inflammationResultsTen patientsStudy drugAdverse eventsCytokine levelsFactor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial
Sera VA, Stevens AE, Song HK, Rodriguez VM, Tibayan FA, Treggiari MM. Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial. Pilot And Feasibility Studies 2021, 7: 137. PMID: 34215339, PMCID: PMC8252226, DOI: 10.1186/s40814-021-00873-5.Peer-Reviewed Original ResearchFactor Eight Inhibitor Bypassing ActivityCardiac surgeryPilot trialTransfusion requirementsRescue therapyLarge trialsProtocol adherenceBlood productsHigh-risk cardiac surgeryProthrombin complex concentrate administrationPlacebo-controlled pilot trialFactor VIII inhibitor bypass activityLarge pivotal trialsReduction of transfusionBlood product transfusionEnd of CPBTertiary referral hospitalHypothermic circulatory arrestTermination of CPBPost-cardiopulmonary bypassProthrombin complex concentrateBlinded administrationProduct transfusionResultsTwenty patientsStudy drug
2015
Dexmedetomidine Does Not Affect Evoked Potentials During Spine Surgery
Rozet I, Metzner J, Brown M, Treggiari MM, Slimp JC, Kinney G, Sharma D, Lee LA, Vavilala MS. Dexmedetomidine Does Not Affect Evoked Potentials During Spine Surgery. Anesthesia & Analgesia 2015, 121: 492-501. PMID: 26097987, DOI: 10.1213/ane.0000000000000840.Peer-Reviewed Original ResearchMeSH KeywordsAnesthesia, IntravenousAnesthetics, IntravenousDexmedetomidineDouble-Blind MethodEvoked PotentialsEvoked Potentials, MotorEvoked Potentials, SomatosensoryEvoked Potentials, VisualFemaleHumansHypnotics and SedativesIntraoperative Neurophysiological MonitoringMaleMiddle AgedOrthopedic ProceduresPiperidinesPropofolReaction TimeRemifentanilSpineTime FactorsConceptsEffect of dexmedetomidineVisual EPsSpine surgeryEnd pointElective spine surgeryPlacebo-controlled trialPrimary end pointSecondary end pointsLatency N1Motor EPsPlacebo groupStudy drugAdult patientsNormal salineLatency P1DexmedetomidineSomatosensory EPsIRB approvalRelevant dosesEP recordingInformed consentPatientsSurgeryEvoked PotentialsAnesthesia